Skip to main content

Home/ Dr. Goodyear/ Group items tagged thyroid cancer

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Substantial contribution of extrinsic risk factors to cancer development - 0 views

www.ncbi.nlm.nih.gov/...PMC4836858

cancer lifestyle

shared by Nathan Goodyear on 03 Jan 18 - No Cached
  • Here we provide evidence that intrinsic risk factors contribute only modestly (<10~30%) to cancer development
  • we conclude that cancer risk is heavily influenced by extrinsic factors. These results carry immense consequences for strategizing cancer prevention
  • cancers are proposed to originate from the malignant transformation of normal tissue progenitor and stem cells
  • ...14 more annotations...
  • “Intrinsic processes” include those that result in mutations due to random errors in DNA replication whereas “extrinsic factors” are environmental factors that affect mutagenesis rates (such as UV radiation, ionizing radiation, and carcinogens
  • intrinsic factors do not play a major causal role.
  • intrinsic cancer risk should be determined by the cancer incidence for those cancers with the least risk in the entire group controlling for total stem cell divisions
  • if one or more cancers would feature a much higher cancer incidence, for example, lung cancer among smokers vs. non-smokers, then this most likely reflects additional (and probably extrinsic) risk factors (smoking in this case)
  • Particularly, for breast and prostate cancers, it has long been observed that large international geographical variations exist in their incidences (5-fold for breast cancer, 25-fold for prostate cancer)14, and immigrants moving from countries with lower cancer incidence to countries with higher cancer rates soon acquire the higher risk of their new country
  • Colorectal cancer is another high-incidence cancer that is widely considered to be an environmental disease17, with an estimated 75% or more colorectal cancer risk attributable to diet
  • melanoma, its risk ascribed to sun exposure is around 65–86%
  • non-melanoma basal and squamous skin cancers, ~90% is attributable to UV
  • 75% of esophageal cancer, or head and neck cancer are caused by tobacco and alcohol
  • HPV may cause ~90% cases in cervical cancer23, ~90% cases in anal cancer24, and ~70% in oropharyngeal cancer
  • HBV and HCV may account for ~80% cases of hepatocellular carcinoma
  • H pylori may be responsible for 65–80% of gastric cancer
  • While a few cancers have relatively large proportions of intrinsic mutations (>50%), the majority of cancers have large proportions of extrinsic mutations, for example, ~100% for Myeloma, Lung and Thyroid cancers and ~80–90% for Bladder, Colorectal and Uterine cancers, indicating substantial contributions of carcinogen exposures in the development of most cancers
  • onsistent estimate of contribution of extrinsic factors of >70–90% in most common cancer types. This concordance lends significant credibility to the overall conclusion on the role of extrinsic factors in cancer development
  • Nathan Goodyear on 03 Jan 18
     
    Really great read.  Cancer is a majority lifestyle disease.
Nathan Goodyear

Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expec... - 0 views

www.nature.com/ja201711

Ivermectin cancer

shared by Nathan Goodyear on 19 Mar 18 - No Cached
  • The avermectins are known to possess pronounced antitumor activity
  • Over the past few years, there have been steadily increasing reports that ivermectin may have varying uses as an anti-cancer agent, as it has been shown to exhibit both anti-cancer and anti-cancer stem cell properties
  • In human ovarian cancer and NF2 tumor cell lines, high-dose ivermectin inactivates protein kinase PAK1 and blocks PAK1-dependent growth
  • ...13 more annotations...
  • PAK1 is essential for the growth of more than 70% of all human cancers, including breast, prostate, pancreatic, colon, gastric, lung, cervical and thyroid cancers, as well as hepatoma, glioma, melanoma, multiple myeloma and for neurofibromatosis tumors
  • Ivermectin suppresses breast cancer by activating cytostatic autophagy, disrupting cellular signaling in the process, probably by reducing PAK1 expression
  • Cancer stem cells are a key factor in cancer cells developing resistance to chemotherapies and these results indicate that a combination of chemotherapy agents plus ivermectin could potentially target and kill cancer stem cells, a paramount goal in overcoming cancer
  • Triple-negative breast cancers, which lack estrogen, progesterone and HER2 receptors, account for 10–20% of breast cancers and are associated with poor prognosis
  • Ivermectin addition led to transcriptional modulation of genes associated with epithelial–mesenchymal transition and maintenance of a cancer stem cell phenotype in triple-negative breast cancers cells, resulting in impairment of clonogenic self-renewal in vitro and inhibition of tumor growth and metastasis in vivo
  • Ivermectin-induced cytostatic autophagy also leads to suppression of tumor growth in breast cancer xenografts, causing researchers to believe there is scope for using ivermectin to inhibit breast cancer cell proliferation and that the drug is a potential treatment for breast cancer
  • ivermectin synergizes with the chemotherapy agents cytarabine and daunorubicin to induce cell death in leukemia cells
  • Ivermectin inhibits proliferation and increases apoptosis of various human cancers
  • Activation of WNT-TCF signaling is implicated in multiple diseases, including cancers of the lungs and intestine,
  • A new screening system has found that ivermectin inhibits the expression of WNT-TCF targets
  • It represses the levels of C-terminal β-catenin phosphoforms and of cyclin D1 in an okadaic acid-sensitive manner, indicating its action involves protein phosphatases
  • In vivo, ivermectin selectively inhibits TCF-dependent, but not TCF-independent, xenograft growth without side effects
  • ivermectin has an exemplary safety record, it could swiftly become a useful tool as a WNT-TCF pathway response blocker to treat WNT-TCF-dependent diseases, encompassing multiple cancers.117
  • Nathan Goodyear on 19 Mar 18
     
    Ivermectin shows promise and usefullness in several cancer types.  This is a review article.
Nathan Goodyear

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside - 0 views

www.ncbi.nlm.nih.gov/...PMC5686300

nagalase Gc-MAF cancer

shared by Nathan Goodyear on 29 Jan 18 - No Cached
  • MAF precursor activity has also been lost or reduced after Gc-globulin treatment in some cancer cell lines
  • This appears to result from the deglycosylated ɑ-N-acetylgalactosaminidase (nagalase) secreted from cancerous cells
  • Nagalase has been detected in many cancer patients, but not in healthy individuals
  • ...31 more annotations...
  • Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
  • It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
  • The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
  • It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
  • The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
  • Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
  • Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
  • The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
  • Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
  • Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
  • It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
  • Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
  • Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
  • weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
  • this treatment has been suggested for non-anemic patients
  • Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
  • Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
  • In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
  • individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
  • Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
  • Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
  • There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
  • It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
  • it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
  • The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
  • Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
  • Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
  • It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
  • inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
  • macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
  • Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
  • Nathan Goodyear on 29 Jan 18
     
    great review on Gc-MAF in cancer.  An increase in nagalase blocks Gc-protein to Gc-MAF activity leaving the host immune system compromised.
Nathan Goodyear

Association of Hashimoto's thyroiditis with thyroid cancer - 0 views

erc.endocrinology-journals.org/...845.full

Thyroid thyroid disease Hashimoto's thyroiditis TPO TgAb thyroid nodules

shared by Nathan Goodyear on 13 Apr 15 - No Cached
  • Nathan Goodyear on 13 Apr 15
     
    This prospective study finds association with Thyroid cancer with TgAb and not TPO in those with thyroid nodules.
Nathan Goodyear

Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? - 0 views

www.ncbi.nlm.nih.gov/...PMC2575056

thyroid disease cancer Thyroid Hashimoto's thyroiditis women

shared by Nathan Goodyear on 13 Apr 15 - No Cached
  • Nathan Goodyear on 13 Apr 15
     
    This one size treats all approach that medicine takes in its recommendations to cancer evaluation is BS (forgive my french).  Women with Hashimoto's disease are at increased risk of Papillary Thyroid cancer risk (30%) compared to those without.  
Nathan Goodyear

The association between papillary thyroid carcinoma and histologically proven Hashimoto... - 0 views

www.eje-online.org/...343.abstract

Hashimoto's thyroiditis hypothyroidism Hashimoto hypothyroid papillary thyroid cancer papillary cancer hormone hormones

shared by Nathan Goodyear on 05 Mar 13 - No Cached
  • Nathan Goodyear on 05 Mar 13
     
    patients with Hashimoto's thyroiditis are at increased risk for papillary thyroid cancer.
Nathan Goodyear

INCREASED INCIDENCE OF WELL-DIFFERENTIATED THYROID CANCER ASSOCIATED WITH HASHIMOTO'S T... - 0 views

www.ncbi.nlm.nih.gov/...PMC2430882

Hashimoto's thyroiditis thyroid cancer hormone hormones autoimmune disease inflammation

shared by Nathan Goodyear on 28 Aug 13 - No Cached
  • Nathan Goodyear on 28 Aug 13
     
    Strong link between Hashimoto's thyroiditis and thyroid cancer.  Risk increased 3 fold.
Nathan Goodyear

Thyroidectomy for Hashimoto's thyroiditis: complicat... [Thyroid. 2008] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...18631001

Hashimoto's thyroiditis autoimmune disease inflammation thyroid cancer hormone hormones

shared by Nathan Goodyear on 28 Aug 13 - No Cached
  • Nathan Goodyear on 28 Aug 13
     
    Thyroid cancer increased in those with Hashimoto's thyroiditis.  
Nathan Goodyear

Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study - 0 views

www.ncbi.nlm.nih.gov/...PMC3817335

Hashimoto's thyroiditis thyroid disease autoimmune cancer

shared by Nathan Goodyear on 13 Apr 15 - No Cached
  • Nathan Goodyear on 13 Apr 15
     
    Hashimoto's thyroid disease is associated with increased cancer in women: particularly in this study--Thyroid and colorectal.
Nathan Goodyear

Journal of Endocrinological Investigation - 0 views

www.jendocrinolinvest.it/...abstract.cfm

thyroid cancer thyroid nodules nodules TSH autoimmune TPO anti-thyroglobulin antibodies

shared by Nathan Goodyear on 28 May 13 - No Cached
  • Nathan Goodyear on 28 May 13
     
    elevated autoimmune markers against the thyroid and an elevated TSH are both independent risk factors for thyroid malignancy in those with thyroid nodules.
Nathan Goodyear

The trace element selenium and the thyroid gland. - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...10403185

Selenium Se thyroid gland function iodine cancer

shared by Nathan Goodyear on 10 Nov 14 - No Cached
  • Nathan Goodyear on 10 Nov 14
     
    Selenium is very important in thyroid function, not just Iodine.  Low Se levels significantly correlate with thyroid cancer.
Nathan Goodyear

Clonal relationship between Hashimoto thyroidi... [J Clin Pathol. 2008] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...18006670

thyroid cancer Hashimoto's thyroiditis autoimmune disease inflammation hormone hormones

shared by Nathan Goodyear on 28 Aug 13 - No Cached
  • Nathan Goodyear on 28 Aug 13
     
    this study proposes link between Hashimoto's thyroiditis and thyroid lymphoma.
Nathan Goodyear

Treatment With Metformin Is Associated With Higher Remission Rate in Diabetic Patients ... - 0 views

jcem.endojournals.org/...3269.abstract

diabetes cancer metformin thyroid

shared by Nathan Goodyear on 21 Aug 13 - No Cached
  • Nathan Goodyear on 21 Aug 13
     
    Small study in thyroid cancer finds that metformin reduces tumor size versus those not treated with metformin. The individuals in this study were Diabetics also.
Nathan Goodyear

Estradiol-induced proliferation of papillary and follicular thyroid cancer ce... - 0 views

www.spandidos-publications.com/...1067

thyroid papillary follicular cancer estrogen estradiol hormone hormones ER alpha ER-alpha ER beta ER-beta PR receptors progesterone

shared by Nathan Goodyear on 25 Nov 13 - No Cached
  • Nathan Goodyear on 25 Nov 13
     
    Estradiol increased thyroid papillary and follicular cancer cells via both ER alpha and ER beta in this study.  What is also interesting is that estradiol did not increase PR expression.
Nathan Goodyear

Hormonal Factors and the Risk of Papillary Thyroid Cancer in the California Teachers St... - 0 views

www.ncbi.nlm.nih.gov/...PMC3288117

papillary thyroid cancer progesterone hormone hormones

shared by Nathan Goodyear on 25 Nov 13 - No Cached
  • Nathan Goodyear on 25 Nov 13
     
    States of low progesterone and/or high estrogen to progesterone are associated with increased papillary thyroid cancer.
Nathan Goodyear

High iodine effects on the proliferation, apoptosis, and migration of papillary thyroid... - 0 views

pubmed.ncbi.nlm.nih.gov/31563816

thyroid cancer cancer Iodine

shared by Nathan Goodyear on 06 Aug 21 - No Cached
  • Nathan Goodyear on 06 Aug 21
     
    Iodine inhibits proliferation and promotes apoptosis in BRAF + papillary thyroid cancer
Nathan Goodyear

Targeted near infrared hyperthermia combined with immune stimulation for optimized ther... - 0 views

www.ncbi.nlm.nih.gov/...PMC4872755

HSP70 thyroid cancer quercetin hyperthermia

shared by Nathan Goodyear on 05 Nov 21 - No Cached
  • Nathan Goodyear on 05 Nov 21
     
    Quercetin inhibits HSP70 and improves efficacy of HT in thyroid cancer in vitro and in vivo studies.
Nathan Goodyear

Effects of thyroid hormones on hu... [J Steroid Biochem Mol Biol. 2008] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...18328691

triiodothyronine T3 thyroid hormone hormones breast cancer E2 Estradiol

shared by Nathan Goodyear on 13 Aug 14 - No Cached
  • Nathan Goodyear on 13 Aug 14
     
    T3 may promote cancer cell proliferation says study.  Triiodothyronine was found to enhance the MCF-7 and T47-D breast cancer cell lines.  The conclusion of the abstract discusses a role of T3 in breast cancer development and progression.  This likely has more to do with progression than development through increased metabolism of the cell lines.
Nathan Goodyear

The Colorful Diversity of Thyroid Hormone Metabolites - 0 views

www.ncbi.nlm.nih.gov/...PMC6587369

T3 cancer thyroid hormones T4 rT3 reverse T3

shared by Nathan Goodyear on 30 Jan 21 - No Cached
  • Nathan Goodyear on 30 Jan 21
     
    Though not specifically discussing the relationship of thyroid hormones and cancer, the implication is strong.
1 - 20 of 90 Next › Last »
Showing 20▼ items per page